{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:14:37Z","timestamp":1792782877106,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Research Foundation of Korea","award":["2022R1I1A2066092"],"award-info":[{"award-number":["2022R1I1A2066092"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Research Foundation of Korea","award":["2022R1C1C2004274"],"award-info":[{"award-number":["2022R1C1C2004274"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Research Foundation of Korea","award":["2020R1A5A2017323"],"award-info":[{"award-number":["2020R1A5A2017323"]}],"id":[{"id":"https:\/\/ror.org\/013aysd81","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Priority Research Centers Program through the National Research Foundation","award":["2016R1A6A1A03007648"],"award-info":[{"award-number":["2016R1A6A1A03007648"]}]},{"name":"the BK21 FOUR","award":["5199990614732"],"award-info":[{"award-number":["5199990614732"]}]},{"name":"the BK21 FOUR","award":["2120240615414"],"award-info":[{"award-number":["2120240615414"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s10120-025-01664-0","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T01:59:45Z","timestamp":1759197585000},"page":"1125-1143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of adenovirus-based oncolytic virus to induce EBV lytic reactivation"],"prefix":"10.1007","volume":"28","author":[{"given":"Sun Hee","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeji","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghyun","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyeon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Woog","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyosun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0622-5839","authenticated-orcid":false,"given":"Hyojeung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"1664_CR1","doi-asserted-by":"publisher","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","volume":"68","author":"VT DeVita","year":"2008","unstructured":"DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643\u201353.","journal-title":"Cancer Res"},{"key":"1664_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire WL. Human-breast cancer - correlation of relapse and survival with amplification of the Her-2 Neu oncogene. Science. 1987;235:177\u201382.","journal-title":"Science"},{"key":"1664_CR3","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673\u201384.","journal-title":"N Engl J Med"},{"key":"1664_CR4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrc2656","volume":"9","author":"J Baselga","year":"2009","unstructured":"Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463\u201375.","journal-title":"Nat Rev Cancer"},{"key":"1664_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"LP Chen","year":"2013","unstructured":"Chen LP, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227\u201342.","journal-title":"Nat Rev Immunol"},{"key":"1664_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"1664_CR7","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"1664_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.mt.6300108","volume":"15","author":"E Kelly","year":"2007","unstructured":"Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15:651\u20139.","journal-title":"Mol Ther"},{"key":"1664_CR9","doi-asserted-by":"publisher","first-page":"1012806","DOI":"10.3389\/fimmu.2022.1012806","volume":"13","author":"M Jafari","year":"2022","unstructured":"Jafari M, Kadkhodazadeh M, Shapourabadi MB, Goradel NH, Shokrgozar MA, Arashkia A, et al. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses. Front Immunol. 2022;13:1012806.","journal-title":"Front Immunol"},{"key":"1664_CR10","first-page":"A22","volume":"25","author":"R Sanju\u00e1n","year":"2014","unstructured":"Sanju\u00e1n R, Garijo R, Hern\u00e1ndez P, Rivas C, Diallo JS. Experimental evolution of a p53-specific oncolytic vesicular stomatitis virus. Hum Gene Ther. 2014;25:A22\u2013A22.","journal-title":"Hum Gene Ther"},{"key":"1664_CR11","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/gt.2008.72","volume":"15","author":"TC Liu","year":"2008","unstructured":"Liu TC, Kirn D. Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther. 2008;15:877\u201384.","journal-title":"Gene Ther"},{"key":"1664_CR12","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","volume":"107","author":"H Fukuhara","year":"2016","unstructured":"Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373\u20139.","journal-title":"Cancer Sci"},{"key":"1664_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/OV.S143808","volume":"7","author":"MB Phillips","year":"2018","unstructured":"Phillips MB, Stuart JD, Stewart RMR, Berry JTL, Mainou BA, Boehme KW. Current understanding of reovirus oncolysis mechanisms. Oncolytic Virotherapy. 2018;7:53\u201363.","journal-title":"Oncolytic Virotherapy"},{"key":"1664_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113219","author":"L M\u00fcller","year":"2020","unstructured":"M\u00fcller L, Berkeley R, Barr T, Ilett E, Errington-Mais F. Past, present and future of oncolytic reovirus. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12113219.","journal-title":"Cancers"},{"key":"1664_CR15","doi-asserted-by":"publisher","first-page":"707290","DOI":"10.3389\/fmicb.2021.707290","volume":"12","author":"YQ Zhao","year":"2021","unstructured":"Zhao YQ, Liu ZM, Li L, Wu J, Zhang HB, Zhang HH, et al. Oncolytic adenovirus: prospects for cancer immunotherapy. Front Microbiol. 2021;12:707290.","journal-title":"Front Microbiol"},{"key":"1664_CR16","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1158\/2326-6074.TUMIMM14-B51","volume":"3","author":"S Bramante","year":"2015","unstructured":"Bramante S, Kaufmann JK, Veckman V, Nettelbeck DM, Hemminki O, Liikanen I, et al. Treatment of melanoma with a serotype 5\/3 chimeric oncolytic adenovirus coding for GM-CSF: results in vitro, in rodents and in humans. Cancer Immunol Res. 2015;3:1775\u201383.","journal-title":"Cancer Immunol Res"},{"key":"1664_CR17","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/mt.2010.161","volume":"18","author":"A Koski","year":"2010","unstructured":"Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, et al. Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther. 2010;18:1874\u201384.","journal-title":"Mol Ther"},{"key":"1664_CR18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.7150\/thno.3724","volume":"2","author":"JJ Rojas","year":"2012","unstructured":"Rojas JJ, Thorne SH. Theranostic potential of oncolytic vaccinia virus. Theranostics. 2012;2:363\u201373.","journal-title":"Theranostics"},{"key":"1664_CR19","doi-asserted-by":"publisher","first-page":"10951","DOI":"10.1128\/JVI.76.21.10951-10959.2002","volume":"76","author":"WH Feng","year":"2002","unstructured":"Feng WH, Westphal E, Mauser A, Raab-Traub N, Gulley ML, Busson P, et al. Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. J Virol. 2002;76:10951\u20139.","journal-title":"J Virol"},{"key":"1664_CR20","doi-asserted-by":"publisher","first-page":"12543","DOI":"10.1128\/JVI.76.24.12543-12552.2002","volume":"76","author":"A Mauser","year":"2002","unstructured":"Mauser A, Holley-Guthrie E, Zanation A, Yarborough W, Kaufmann W, Klingelhutz A, et al. The Epstein-Barr virus immediate-early protein BZLF1 induces expression of E2F\u20131 and other proteins involved in cell cycle progression in primary keratinocytes and gastric carcinoma cells. J Virol. 2002;76:12543\u201352.","journal-title":"J Virol"},{"key":"1664_CR21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.omtn.2018.04.003","volume":"11","author":"C Chen","year":"2018","unstructured":"Chen C, Yue D, Lei L, Wang H, Lu J, Zhou Y, et al. Promoter-operating targeted expression of gene therapy in cancer: current stage and prospect. Mol Ther Nucleic Acids. 2018;11:508\u201314.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1664_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020879","author":"S Yano","year":"2021","unstructured":"Yano S, Tazawa H, Kishimoto H, Kagawa S, Fujiwara T, Hoffman RM. Real-time fluorescence image-guided oncolytic virotherapy for precise cancer treatment. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22020879.","journal-title":"Int J Mol Sci"},{"key":"1664_CR23","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1128\/JVI.02794-15","volume":"90","author":"H Kim","year":"2016","unstructured":"Kim H, Choi H, Lee SK. Epstein-Barr virus microRNA miR-BART20-5p suppresses lytic induction by inhibiting BAD-mediated caspase-3-dependent apoptosis. J Virol. 2016;90:1359\u201368.","journal-title":"J Virol"},{"key":"1664_CR24","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1002\/ijc.27439","volume":"131","author":"KF Hui","year":"2012","unstructured":"Hui KF, Ho DN, Tsang CM, Middeldorp JM, Tsao GS, Chiang AK. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma. Int J Cancer. 2012;131:1930\u201340.","journal-title":"Int J Cancer"},{"key":"1664_CR25","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1158\/1078-0432.CCR-0349-03","volume":"10","author":"RL Chu","year":"2004","unstructured":"Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res. 2004;10:5299\u2013312.","journal-title":"Clin Cancer Res"},{"key":"1664_CR26","doi-asserted-by":"publisher","first-page":"13360","DOI":"10.1128\/JVI.01850-12","volume":"86","author":"SR Hagemeier","year":"2012","unstructured":"Hagemeier SR, Barlow EA, Meng Q, Kenney SC. The cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli. J Virol. 2012;86:13360\u201370.","journal-title":"J Virol"},{"key":"1664_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/aps.2009.16","volume":"30","author":"YM Wu","year":"2009","unstructured":"Wu YM, Zhang KJ, Yue XT, Wang YQ, Yang Y, Li GC, et al. Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7\/IL-24. Acta Pharmacol Sin. 2009;30:467\u201377.","journal-title":"Acta Pharmacol Sin"},{"key":"1664_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jconrel.2015.09.031","volume":"220","author":"H Saari","year":"2015","unstructured":"Saari H, Lazaro-Ibanez E, Viitala T, Vuorimaa-Laukkanen E, Siljander P, Yliperttula M. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells. J Control Release. 2015;220:727\u201337.","journal-title":"J Control Release"},{"key":"1664_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s41231-023-00144-w","volume":"8","author":"S Thoidingjam","year":"2023","unstructured":"Thoidingjam S, Sriramulu S, Freytag S, Brown SL, Kim JH, Chetty IJ, et al. Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health. Transl Med Commun. 2023;8:11.","journal-title":"Transl Med Commun"},{"key":"1664_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/v16030377","author":"L Scarsella","year":"2024","unstructured":"Scarsella L, Ehrke-Schulz E, Paulussen M, Thal SC, Ehrhardt A, Aydin M. Advances of recombinant adenoviral vectors in preclinical and clinical applications. Viruses. 2024. https:\/\/doi.org\/10.3390\/v16030377.","journal-title":"Viruses"},{"key":"1664_CR31","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrc1452","volume":"4","author":"LS Young","year":"2004","unstructured":"Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4:757\u201368.","journal-title":"Nat Rev Cancer"},{"key":"1664_CR32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1440-1827.2010.02533.x","volume":"60","author":"M Fukayama","year":"2010","unstructured":"Fukayama M. Epstein-Barr virus and gastric carcinoma. Pathol Int. 2010;60:337\u201350.","journal-title":"Pathol Int"},{"key":"1664_CR33","first-page":"4908","volume":"6","author":"C Heise","year":"2000","unstructured":"Heise C, Lemmon M, Kirn D. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin Cancer Res. 2000;6:4908\u201314.","journal-title":"Clin Cancer Res"},{"key":"1664_CR34","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1186\/s12885-018-4453-z","volume":"18","author":"Y Hirooka","year":"2018","unstructured":"Hirooka Y, Kasuya H, Ishikawa T, Kawashima H, Ohno E, Villalobos IB, et al. A phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer. BMC Cancer. 2018;18:596.","journal-title":"BMC Cancer"},{"key":"1664_CR35","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658\u201370.","journal-title":"Nat Biotechnol"},{"key":"1664_CR36","volume":"31","author":"A Yang","year":"2023","unstructured":"Yang A, Zhang Z, Chaurasiya S, Park AK, Lu J, Kim SI, et al. Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases. Mol Ther. 2023;31:100734.","journal-title":"Mol Ther"},{"key":"1664_CR37","first-page":"6070","volume":"62","author":"T Reid","year":"2002","unstructured":"Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002;62:6070\u20139.","journal-title":"Cancer Res"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01664-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01664-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01664-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:03:19Z","timestamp":1790726599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01664-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1664"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01664-0","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}